A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

BACKGROUND: Cisplatin, a chemotherapy used to treat solid tumors, causes acute kidney injury (AKI), a known risk factor for chronic kidney disease and mortality. AKI diagnosis relies on biomarkers which are only measurable after kidney damage has occurred and functional impairment is apparent; this...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Anshika, Huang, Ryan, Lee, Jasmine, Jawa, Natasha, Lim, Yong Jin, Guron, Mike, Abish, Sharon, Boutros, Paul C., Brudno, Michael, Carleton, Bruce, Cuvelier, Geoffrey D. E., Gunaratnam, Lakshman, Ho, Cheryl, Adeli, Khosrow, Kuruvilla, Sara, Lajoie, Giles, Liu, Geoffrey, Nathan, Paul C., Rod Rassekh, Shahrad, Rieder, Michael, Waikar, Sushrut S., Welch, Stephen A., Weir, Matthew A., Winquist, Eric, Wishart, David S., Zorzi, Alexandra P., Blydt-Hansen, Tom, Zappitelli, Michael, Urquhart, Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Clinical Research Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606978/
https://www.ncbi.nlm.nih.gov/pubmed/34820133
http://dx.doi.org/10.1177/20543581211057708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606978/
https://www.ncbi.nlm.nih.gov/pubmed/34820133
http://dx.doi.org/10.1177/20543581211057708

Ejemplares similares